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Abstract: The aim of this study was to evaluate the expression of autophagy-related proteins and their clinical impli-
cations in primary and metastatic breast cancer. Immunohistochemical staining of autophagy-related proteins (be-
clin-1, LC3A, LC3B) in 162 metastatic breast cancers (bone metastasis = 47, brain metastasis = 39, liver metastasis 
= 24, and lung metastasis = 52) was performed using tissue microarray (TMA). The expression of autophagy-related 
proteins in tumor cells varied according to metastatic site. Tumoral LC3A expression was high in brain and lung me-
tastasis (P<0.001), stromal LC3A in bone metastasis (P<0.001), and stromal LC3B in liver metastasis (P = 0.017), 
respectively. In univariate analysis, beclin-1 positivity (P = 0.002) was associated with shorter overall survival (OS). 
In analysis by metastatic site, beclin-1 positivity (P = 0.002) and activated autophagy status (P = 0.009) in bone 
metastasis as well as beclin-1 positivity (P = 0.016) and tumoral LC3A positivity (P = 0.038) in lung metastasis were 
related to shorter OS. In conclusion, the expression of autophagy-related proteins varied according to the site of 
metastasis and was correlated with prognosis.
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Introduction 
Breast cancer is associated with high morbidity 
and mortality rates due to frequent metastasis 
to sites such as the lung, brain, liver, and bone 
[1, 2], with brain and bone being the most well-
characterized [3-8]. The general mechanism of 
tumor metastasis is interaction between tumor 
cells and host tissue, and it includes adhesion, 
proteolysis, invasion, and angiogenesis [2, 9]. 
Because not all tumors show the same meta-
static pattern, the seed and soil hypothesis pro-
poses that a specific tumor (seed) can survive 
in a specific organ (soil) [10]. Metastatic breast 
cancer characteristics differ according to meta-
static site; previous reports show that young 
age, ER negativity, HER-2 overexpression, EGFR 
overexpression, and basal subtype are specific 
for brain metastasis [5-7], and factors suggest-
ing bone metastasis include lower histologic 
grade, ER positivity/PR negativity, strand gro- 
wth pattern, and the presence of fibrotic foci [4, 
11, 12].
Cancer cells can survive difficult conditions 
such as hypoxia, lack of nutrients, or chemo-
therapy. However, highly aggressive malignant 
tumors often have high metabolic demand and, 
in some cases, require an alternative metabolic 
pathway. These cells can use energy supplied 
by recycling cytoplasmic components through 
autophagy [13, 14]. Hence, we hypothesize that 
autophagy plays an important role in tumor 
metabolism. Several proteins can be used to 
evaluate the activity of autophagy including 
beclin-1, which participates in the nucleation 
process [13, 14], and LD3, which participates in 
the elongation process and helps form autopha-
gosomes [15-17]. These autophagy pathways 
are under current investigation as new possible 
targets for tumor therapy [18-21]. Since target 
therapy is used in both primary and metastatic 
tumors, evaluation of autophagy status at pri-
mary and metastatic sites is necessary. How- 
ever, tumor characteristics vary according to 
metastatic site and there are few studies 
focused on autophagy at these sites. Therefore, 
the aim of this study is to investigate the ex- 
pression of autophagy-related proteins at dif-
ferent metastatic sites and the resulting clini- 
cal implications.
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Materials and methods
Patient selection
Data files were selected for invasive primary 
breast cancer and metastasis to distant or- 
gans (liver, lung, brain, and bone) from the 
Department of Pathology of Severance Hos- 
pital. Only patients with diagnosed invasive 
ductal carcinoma were included. This study was 
approved by the institutional review board. A 
total of 162 cases were included, with 49 cases 
paired between the primary tumor site and 
metastatic site. All slides were reviewed and 
pathologic diagnoses were approved by 2 
pathologists (JSK and WJ). Histological grade 
was assessed using the Nottingham grading 
system [22]. 
Immunohistochemistry 
Antibodies used for immunohistochemistry 
are shown in Table 1. Formalin-fixed, paraffin-
embedded tissue sections were used for IHC 
staining. Tissue was sectioned to 3-μm thick-
ness, deparaffinized in xylene, and rehydrated 
with alcohol solution. Detection was performed 
using a Ventana Discovery XT automated stain-
er (Ventana Medical System, Tucson, AZ, USA). 
Antigen retrieval was performed using CC1 buf-
fer (Cell Conditioning 1; citrate buffer Ph 6.0, 
Ventan Medical System). IHC staining included 
adequate positive and negative controls.
Interpretation of immunohistochemical results 
A cut-off value of ≥1% positively stained nuclei 
was used to define ER and PR positivity [23]. 
HER-2 staining was analyzed according to the 
American Society of Clinical Oncology (ASCO)/
College of American Pathologists (CAP) guide-
lines using the following categories: 0 = no 
immunostaining; 1+ = weak incomplete mem-
branous staining, less than 10% of tumor cells; 
2+ = complete membranous staining, either 
uniform or weak, in at least 10% of tumor cells; 
and 3+ = uniform intense membranous stain-
ing in at least 30% of tumor cells [24]. HER-2 
immunostaining was considered positive when 
strong (3+) membranous staining was observed, 
whereas cases with 0 to 1+ were regarded as 
negative.
IHC staining was evaluated by calculating the 
proportion of stained cells multiplied by immu-
nostaining intensity. The proportion of stained 
cells was scored as 0 = negative, 1 = positive 
below than 30%, and 2 = positive when 30% or 
more. Immunostaining intensity was defined as 
0 = negative, 1 = weak, 2 = moderate, and 3 = 
strong. The multiplication score of the propor-
tion of stained cells by immunostaining inten-
sity was defined as negative if 0 or 1, and posi-
tive if 2-6 [25]. Cases with two or more positive 
autophagy-related markers were considered to 
be autophagy-activated.
Statistical analysis   
Statistical analyses were performed using 
SPSS for Windows, version 12.0 (SPSS Inc., 
Chicago, IL, USA). Correlation analysis of immu-
nostaining results between primary breast can-
cer and metastatic breast cancer were calcu-
lated by the McNemar test. Comparative statis-
tics were performed using chi-squared analy-
sis. Statistical significance was assumed when 
P<0.05. Kaplan-Meier survival curves and log-
rank statistics were employed to evaluate time 
to tumor metastasis and time to survival. 
Results 
Basal characteristics of patients (Table 2)
Among 162 patients, lung metastasis was 
observed in 52 cases (32.1%), bone metastasis 
in 47 cases (29%), brain metastasis in 39 cases 
(24.1%), and liver metastasis in 24 cases 
(14.8%). ER positivity and PR positivity were 
high in bone and liver metastases (P<0.001), 
and HER-2 positivity was high in brain metas- 
tasis (P = 0.017). There were more luminal A 
types in bone and liver metastases and more 
TNBC types in brain and lung metastases 
(P<0.001).
Expression of autophagy-related proteins in 
breast cancer metastasis according to meta-
static site (Table 3; Figure 1)
Analysis of the expression of autophagy-related 
proteins showed that the expression of tumoral 
Table 1. Clone, dilution, and source of antibod-
ies used
Antibody Clone Dilution Source
Beclin-1 Polyclonal 1:100 Abcam, Cambridge, UK
LC3A EP1528Y 1:100 Abcam, Cambridge, UK
LC3B SQSTM1 1:100 Abcam, Cambridge, UK
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LC3A (P = 0.001), stromal LC3A (P = 0.001), 
and stromal LC3B (P = 0.017) were different 
among metastatic sites. Tumoral LC3A expres-
sion was high in brain and lung metastases, 
Table 2. Basal clinicopathologic characteristics of breast cancer metastasis according to the meta-
static sites 
Parameters TotalN = 162 (%)
Bone 
metastasis 
N = 47 (%)
Brain
metastasis
n = 39 (%)
Liver 
metastasis
N = 24 (%)
Lung
metastasis
n = 52 (%)
P-value
Age (years) 0.022
    ≤50 81 (50.0) 27 (57.4) 17 (43.6) 6 (25.0) 31 (59.6)
    >50 81 (50.0) 20 (42.6) 22 (56.4) 18 (75.0) 21 (40.4)
ER <0.001
    Negative 69 (42.6) 8 (17.0) 26 (66.7) 6 (25.0) 29 (55.8)
    Positive 93 (57.4) 39 (83.0) 13 (33.3) 18 (75.0) 23 (44.2)
PR <0.001
    Negative 109 (67.3) 23 (48.9) 38 (97.4) 12 (50.0) 36 (69.2)
    Positive 53 (32.7) 24 (51.1) 1 (2.6) 12 (50.0) 16 (30.8)
HER-2 0.017
    Negative 114 (70.4) 38 (80.9) 20 (51.3) 19 (79.2) 37 (71.2)
    Positive 48 (29.6) 9 (19.1) 19 (48.7) 5 (20.8) 15 (28.8)
Molecular subtypes <0.001
    Luminal A 67 (41.4) 33 (70.2) 4 (10.3) 15 (62.5) 15 (28.8)
    Luminal B 27 (16.7) 7 (14.9) 9 (23.1) 3 (12.5) 8 (15.4)
    HER-2 30 (18.5) 5 (10.6) 12 (30.8) 3 (12.5) 10 (19.2)
    TNBC 38 (23.5) 2 (4.3) 14 (35.9) 3 (12.5) 19 (36.5)
Patients death 53 (32.7) 23 (48.9) 11 (28.2) 7 (29.2) 12 (23.1) 0.040
Table 3. Expression of autophagy related proteins in tumor cell compartment of breast cancer metas-
tasis according to the metastatic sites 
Parameters TotalN = 162 (%)
Bone 
metastasis
N = 47 (%)
Brain
metastasis
n = 39 (%)
Liver 
metastasis
N = 24 (%)
Lung
metastasis
n = 52 (%)
P-value
Beclin-1 0.739
    Negative 97 (59.9) 26 (55.3) 25 (64.1) 16 (66.7) 30 (57.7)
    Positive 65 (40.1) 21 (44.7) 14 (35.9) 8 (33.3) 22 (42.3)
LC3A (T) 0.001
    Negative 137 (84.6) 45 (95.7) 26 (66.7) 23 (95.8) 43 (82.7)
    Positive 25 (15.4) 2 (4.3) 13 (33.3) 1 (4.2) 9 (17.3)
LC3A (S) 0.001
    Negative 138 (85.2) 34 (72.3) 30 (76.9) 24 (100.0) 50 (96.2)
    Positive 24 (14.8) 13 (27.7) 9 (23.1) 0 (0.0) 2 (3.8)
LC3B (T) 0.281
    Negative 112 (69.1) 32 (68.1) 28 (71.8) 20 (83.3) 32 (61.5)
    Positive 50 (30.9) 15 (31.9) 11 (28.2) 4 (16.7) 20 (38.5)
LC3B (S) 0.017
    Negative 157 (96.9) 45 (95.7) 39 (100.0) 21 (87.5) 52 (100.0)
    Positive 5 (3.1) 2 (4.3) 0 (0.0) 3 (12.5) 0 (0.0)
Autophagy status 0.363
    Non-activated 119 (73.5) 33 (70.2) 31 (79.5) 20 (83.3) 35 (67.3)
    Activated 43 (26.5) 14 (29.8) 8 (20.5) 4 (16.7) 17 (32.7)
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Figure 1. Expression of autophagy-related proteins in metastatic breast cancer according to metastatic site. Tumoral 
LC3A expression was high in brain and lung metastases, while stromal LC3A and stromal LC3B were high in brain 
and liver metastases, respectively.
Table 4. Correlation of expression of autophagy related proteins between primary and metastatic 
breast cancer according to the metastatic sites
Parameters 
Total Bone metastasis Brain metastasis Liver metastasis Lung metastasis
N = 49(%) P-value N = 13 (%) P-value N = 9 (%) P-value N = 4 (%) P-value N = 23 (%) P-value
Beclin-1 0.424 0.500 0.375 1.000 0.688
    (+) → (+) 5 (10.2) 1 (7.7) 1 (11.1) 0 (0.0) 3 (13.0)
    (+) → (-) 9 (18.4) 0 (0.0) 4 (44.4) 1 (25.0) 4 (17.4)
    (-) → (+) 5 (10.2) 2 (15.4) 1 (11.1) 0 (0.0) 2 (8.7)
    (-) → (-) 30 (61.2) 10 (76.9) 3 (33.3) 3 (75.0) 14 (60.9)
LC3A 0.688 n/a 1.000 1.000 0.625
    (+) → (+) 4 (8.2) 0 (0.0) 2 (22.2) 0 (0.0) 2 (8.7)
    (+) → (-) 2 (4.1) 0 (0.0) 0 (0.0) 1 (25.0) 1 (4.3)
    (-) → (+) 4 (8.2) 0 (0.0) 1 (11.1) 0 (0.0) 3 (13.0)
    (-) → (-) 39 (79.6) 13 (100.0) 6 (66.7) 3 (75.0) 17 (73.9)
LC3B 0.815 1.000 1.000 1.000 1.000
    (+) → (+) 7 (14.3) 2 (15.4) 1 (11.1) 0 (0.0) 4 (17.4)
    (+) → (-) 10 (20.4) 2 (15.4) 3 (33.3) 0 (0.0) 5 (21.7)
    (-) → (+) 8 (16.3) 1 (7.7) 2 (22.2) 1 (25.0) 4 (17.4)
    (-) → (-) 24 (49.0) 8 (61.5) 3 (33.3) 3 (75.0) 10 (43.5)
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Figure 2. Correlation between pathologic factors and expression of autophagy-related proteins in metastatic breast 
cancer.
Figure 3. Correlation between pathologic factors and expression of autophagy-related proteins according to meta-
static site.
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while stromal LC3A expression was high in 
bone metastases and stromal LC3B expression 
was high in liver metastases.
Correlation of expression of autophagy-related 
proteins with primary and metastatic breast 
cancer according to metastatic site (Table 4) 
Of 49 paired cases of primary tumor and its 
metastatic site, there were no differences in 
the expression of autophagy-related proteins 
between primary and metastatic breast can- 
cer.
Correlation between pathologic factors and 
expression of autophagy-related proteins 
(Figure 2)
ER negativity was related to beclin-1 positivity 
(P = 0.003), LC3A positivity (P = 0.001), and 
activated autophagy status (P = 0.006). PR 
negativity was related to LC3B positivity (P = 
0.002), and HER-2 positivity was related to 
stromal LC3A positivity (P = 0.001). Beclin-1 po- 
sitivity (P = 0.003), LC3A positivity (P<0.001), 
and autophagy status (P = 0.006) varied ac- 
cording to molecular subtype, the expressions 
of beclin-1 and LC3A were high and activated 
autophagy status showed in TNBC. 
Correlation between pathologic factors and 
expression of autophagy-related proteins ac-
cording to metastatic site (Figure 3)
In bone metastasis, ER negativity was related 
to stromal LC3A (P<0.001), PR negativity was 
related to LC3B positivity (P<0.001), and HER-2 
type was related to stromal LC3A and LC3B 
expression (P = 0.003, and 0.001, respective-
ly). ER negativity was associated with beclin-1 
positivity (P = 0.001) and HER-2 negativity was 
associated with LC3A positivity (P = 0.003) in 
brain metastasis. In lung metastasis, beclin-1 
positivity was related to ER negativity (P = 
0.001) and TNBC (P = 0.003).
The impact of autophagy-related proteins on 
patient prognosis (Table 5; Figure 4)
Univariate analysis revealed that beclin-1 
positivity (P = 0.002) was related to shorter 
overall survival (OS). Analysis by metastatic 
site showed that beclin-1 positivity (P = 0.002) 
and activated autophagy status (P = 0.009) 
in bone metastasis, and beclin-1 positivity 
(P = 0.016) and tumoral LC3A positivity (P = 
0.038) in lung metastasis, correlated with sh- 
orter OS.
Table 5. Univariate analysis of the impact of expression of autophagy related proteins in metastatic 
breast cancers on overall survival by the log-rank test
Parameters
Total
N = 162 (%)
Bone metastasis
N = 47 (%)
Brain metastasis
N = 39 (%)
Liver metastasis
N = 24 (%)
Lung metastasis
N = 52 (%)
Mean survival
(95% CI) 
months
P-
value
Mean survival
(95% CI) 
months
P-
value
Mean survival
(95% CI) 
months
P-
value
Mean survival
(95% CI) 
months
P-
value
Mean survival
(95% CI) 
months
P-
value
Beclin-1 0.002 0.004 0.788 0.850 0.016
    Negative 127 (111-143) 113 (84-143) 140 (77-131) 80 (58-103) 150 (125-175)
    Positive 61 (52-71) 51 (39-63) 77 (55-98) 66 (44-88) 59 (45-73)
LC3A (T) 0.249 0.441 0.870 n/a 0.038
    Negative 113 (99-128) 85 (64-107) 85 (67-103) n/a 139 (115-163)
    Positive 80 (48-112) 58 (26-90) 118 (84-152) n/a 51 (29-73)
LC3A (S) 0.520 0.187 0.678 n/a n/a
    Negative 110 (94-125) 86 (65-106) 108 (83-134) n/a n/a
    Positive 78 (58-99) 63 (34-93) 90 (65-115) n/a n/a
LC3B (T) 0.588 0.123 0.147 n/a 0.732
    Negative 113 (97-130) 93 (67-118) 116 (92-141) n/a 126 (96-156)
    Positive 104 (83-126) 57 (40-74) 63 (38-87) n/a 128 (96-161)
LC3B (S) 0.597 n/a n/a 0.232 n/a
    Negative 111 (97-125) n/a n/a 86 (66-106) n/a
    Positive 45 (36-54) n/a n/a 40 (28-51) n/a
Autophagy status 0.079 0.009 0.186 n/a 0.737
    Non-activated 119 (104-134) 101 (75-128) 113 (89-136) n/a 132 (106-159)
    Activated 65 (54-76) 50 (35-65) 63 (32-93) n/a 69 (54-83)
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Figure 4. The impact of autophagy-related proteins on patient prognosis in metastatic breast cancer (A), bone metastasis (B, C), and lung metastasis (D, E).
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Discussion
In this study, we analyzed the expression of 
autophagy-related proteins in primary and met-
astatic tumors. Results showed a difference in 
the expression of autophagy-related proteins 
according to metastatic site. Tumoral LC3A 
expression was high in brain and lung metasta-
ses (P<0.001), stromal LC3A expression was 
high in bone and brain metastases (P<0.001), 
and stromal LC3B expression was high in liver 
metastases (P = 0.017). There have been few 
studies on autophagy in metastatic breast can-
cer, although one report suggested that expres-
sion of autophagy-related proteins was high in 
TNBC [26]. Our study indicated that tumoral 
LC3A expression is high in brain and lung me- 
tastases (frequent metastatic sites in TNBC) in 
concordance with a previous report.
High expression of autophagy-related proteins 
in TNBC is associated with tumor hypoxia sta-
tus, the representative signal of autophagy 
induction, and pathologic characteristics in- 
clude central necrosis and high proliferative 
activity [31]. We can presume the expression of 
autophagy-related proteins is higher in TNBC 
than in other subtypes due to the increased 
autophagy status by hypoxia.
This study showed that expression of auto- 
phagy-related proteins in the stromal tissue of 
metastatic breast cancer differs according to 
metastatic site. Autophagy in the stroma of 
breast cancer can be explained by the reverse 
Warburg effect, where there is interaction 
between breast cancer cells and cancer stro-
mal cells. According to this theory, glycolysis, 
mitochondrial dysfunction and increased au- 
tophagic activity occur in stromal cells due to 
reactive oxygen species released from breast 
cancer cells. Ketone bodies and lactate pro-
duced by stromal glycolysis enter the tumor 
cell, which produces ATP via oxidative phos-
phorylation [27-29]. 
Previous research has shown that autophagy 
phenotypes differ among molecular subtypes, 
and luminal type shows reverse Warburg effect 
type and TNBC shows Warburg effect type [30]. 
Our study showed high expression of stromal 
LC3A and LC3B in bone and liver metastases, 
respectively, and these are frequent metastatic 
sites for the luminal type. Therefore, the high 
expression of stromal autophagy-related pro-
teins can be attributed to the reverse Warburg 
effect. 
The expression of beclin-1 was related to poor 
prognosis, consistent with previous studies 
showing that expression of beclin-1 corre-
sponded with poor prognosis in colon [31], 
ovarian [32] and hypopharyngeal cancer [33]. 
However, beclin-1 expression correlated with 
good prognosis in other cancers, including 
hepatocellular carcinoma [34] and non-small 
cell lung cancer [35]. Further studies are need-
ed to clarify these incompatible results. 
One limitation of this study is the use of IHC 
staining of autophagy-related proteins like 
beclin-1, LC3A, and LC3B as indicators of 
autophagic activity. Evaluation of autophagic 
activity using a static method like IHC may be 
less accurate because autophagy is a multi-
step, dynamic process. While we expect that 
autophagic activity is increased when LC3A 
and LC3B expression increases, these mark- 
ers can also be increased by autophagosome 
degradation.
The results of this study have a clinical implica-
tion as regulation of autophagy may be a thera-
peutic target for cancer. Recent studies have 
shown that autophagy inhibitors can suppress 
growth of several types of tumors [18-21].
In conclusion, the expression of autophagy-
related proteins differed according to the site 
of metastasis. Tumoral LC3A expression was 
high in cases with brain and lung metastases 
and frequent metastatic sites in TNBC, while 
stromal LC3A and LC3B expression were high 
in cases with bone and liver metastases and 
frequent metastatic sites in more luminal can-
cer types.
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